Literature DB >> 19020911

Methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized children: correlation of molecular analysis with clinical presentation and antibiotic susceptibility testing (ABST) results.

N Abdel-Haq1, H Al-Tatari, P Chearskul, H Salimnia, B I Asmar, M R Fairfax, M Amjad.   

Abstract

The molecular analysis of methicillin-resistant Staphylococcus aureus (MRSA) from 98 children admitted to the Children's Hospital of Michigan, Detroit, MI, with serious MRSA infections during 2006-2007 was correlated with risk factors, clinical features, and antibiotic susceptibility testing (ABST) results. Isolates were characterized by staphylococcal cassette chromosome (SCC) mec type, the presence of Panton-Valentine leukocidin (PVL) genes, repetitive sequence (rep) polymerase chain reaction (PCR) and pulsed-field gel electrophoresis (PFGE), requirement for surgical intervention, antibiograms, and response to therapy. rep-PCR was more rapid than PFGE typing and correlated well. SCCmec type IV-containing isolates caused 92.8% of all infections, but the demographics and diseases associated with subtypes IVa and IVd differed. Subtype IVa (all PFGE type USA300 and PVL-positive) was identified in 81/93 (87.1%) of patients with community-onset (CO) MRSA, including 21/35 of those with risk factors for health care-associated (HA) infection. All other clones were PVL-negative. Subtype IVd (10 isolates; 9 USA800 and 1 eMRSA15) caused mainly HA-MRSA and no skin and soft tissue infections (SSTI). Seven classic HA-MRSA strains (SCCmec types II [6; 3 USA100 and 3 USA600] and III [1; USA200]) caused HA and hospital-onset (HO) infections. Surgical intervention was required in 68/81 patients infected with USA300 and 8/17 of the others. Most USA300 were susceptible (S) to clindamycin (CD) and patients were treated with CD alone or in combination. The other isolates were generally treated with vancomycin (VA) alone or in combination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020911     DOI: 10.1007/s10096-008-0658-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  Epidemiological validation of pulsed-field gel electrophoresis patterns for methicillin-resistant Staphylococcus aureus.

Authors:  D S Blanc; M J Struelens; A Deplano; R De Ryck; P M Hauser; C Petignat; P Francioli
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 2.  Principles and applications of methods for DNA-based typing of microbial organisms.

Authors:  D M Olive; P Bean
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

3.  Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus.

Authors:  Kunyan Zhang; Jo-Ann McClure; Sameer Elsayed; Thomas Louie; John M Conly
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk.

Authors:  B C Herold; L C Immergluck; M C Maranan; D S Lauderdale; R E Gaskin; S Boyle-Vavra; C D Leitch; R S Daum
Journal:  JAMA       Date:  1998-02-25       Impact factor: 56.272

5.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Authors:  G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

6.  Pediatric bone and joint infections caused by Panton-Valentine leukocidin-positive Staphylococcus aureus.

Authors:  Bruno Dohin; Yves Gillet; Rémi Kohler; Gérard Lina; François Vandenesch; Philippe Vanhems; Daniel Floret; Jerome Etienne
Journal:  Pediatr Infect Dis J       Date:  2007-11       Impact factor: 2.129

7.  Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection.

Authors:  Timothy S Naimi; Kathleen H LeDell; Kathryn Como-Sabetti; Stephanie M Borchardt; David J Boxrud; Jerome Etienne; Susan K Johnson; Francois Vandenesch; Scott Fridkin; Carol O'Boyle; Richard N Danila; Ruth Lynfield
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

8.  Evolutionary models of the emergence of methicillin-resistant Staphylococcus aureus.

Authors:  D Ashley Robinson; Mark C Enright
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database.

Authors:  Linda K McDougal; Christine D Steward; George E Killgore; Jasmine M Chaitram; Sigrid K McAllister; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

10.  Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors.

Authors:  Cassandra D Salgado; Barry M Farr; David P Calfee
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

View more
  12 in total

1.  USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit.

Authors:  Carol L Moore; Paola Osaki-Kiyan; Marybeth Perri; Susan Donabedian; Nadia Z Haque; Anne Chen; Marcus J Zervos
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

Review 2.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  Methicillin-resistant Staphylococcus aureus in Spain: molecular epidemiology and utility of different typing methods.

Authors:  Ana Vindel; Oscar Cuevas; Emilia Cercenado; Carmen Marcos; Verónica Bautista; Carol Castellares; Pilar Trincado; Teresa Boquete; Maria Pérez-Vázquez; Mercedes Marín; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2009-04-01       Impact factor: 5.948

4.  Molecular typing and virulence characteristic of methicillin-resistant Staphylococcus aureus isolates from pediatric patients in Bucaramanga, Colombia.

Authors:  Mayra Alejandra Machuca; Luis Miguel Sosa; Clara Isabel González
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

5.  Increased prevalence of methicillin-resistant Staphylococcus aureus nasal colonization in household contacts of children with community acquired disease.

Authors:  Yaseen Rafee; Nahed Abdel-Haq; Basim Asmar; Tanaz Salimnia; Celine Vidaillac Pharm; Michael J Rybak Pharm; Muhammad Amjad
Journal:  BMC Infect Dis       Date:  2012-02-20       Impact factor: 3.090

6.  Molecular Epidemiology Survey of Staphylococcus aureus Panton-Valentine Leukocidin-positive Isolated from Sanandaj, Iran.

Authors:  Abbas Manafi; Mazaher Khodabandehloo; Samaneh Rouhi; Rashid Ramazanzadeh; Babak Shahbazi; Hanar Narenji
Journal:  Adv Biomed Res       Date:  2017-07-25

7.  Infectious and Noninfectious Acute Pericarditis in Children: An 11-Year Experience.

Authors:  Nahed Abdel-Haq; Zeinab Moussa; Mohamed Hani Farhat; Leela Chandrasekar; Basim I Asmar
Journal:  Int J Pediatr       Date:  2018-11-08

8.  Comparison of Multi-Drug Resistant Environmental Methicillin-Resistant Staphylococcus aureus Isolated from Recreational Beaches and High Touch Surfaces in Built Environments.

Authors:  Marilyn C Roberts; Olusegun O Soge; David No
Journal:  Front Microbiol       Date:  2013-04-04       Impact factor: 5.640

Review 9.  The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis.

Authors:  Laura J Shallcross; Ellen Fragaszy; Anne M Johnson; Andrew C Hayward
Journal:  Lancet Infect Dis       Date:  2012-10-26       Impact factor: 25.071

10.  Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves.

Authors:  Som S Chatterjee; Michael Otto
Journal:  Clin Epidemiol       Date:  2013-07-04       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.